Verschiedene Medikamente in Tablettenform (Symbolbild).
Montag, 21.08.2017 20:00 von | Aufrufe: 33

SINOVAC LOSS NOTICE: Rosen Law Firm Reminds Sinovac Biotech Ltd. Investors of Important Deadline in First Filed Class Action - SVA

Verschiedene Medikamente in Tablettenform (Symbolbild). © pixabay.com/CC0 https://pixabay.com

PR Newswire

NEW YORK, Aug. 21, 2017 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Sinovac Biotech Ltd. (NASDAQ: SVA) from April 30, 2013 through May 16, 2017, both dates inclusive (the "Class Period") of the important September 1, 2017 lead plaintiff deadline in the first filed class action commenced by Rosen Law Firm. The lawsuit seeks to recover damages for Sinovac investors under the federal securities laws.

Rosen Law Firm, P.A. Logo

To join the Sinovac class action, go to http://www.rosenlegal.com/cases-1015.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or kchan@rosenlegal.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.

According to the lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) Defendant Weidong Yin, Sinovac's Chairman and CEO, bribed a member of the Chinese Food and Drug Administration to assist Sinovac's vaccine clinical trial and approval; (2) such conduct would subject Sinovac to heightened regulatory scrutiny; and (3) as a result, Sinovac's public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 1, 2017. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-1015.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com or kchan@rosenlegal.com.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.


ARIVA.DE Börsen-Geflüster

Kurse

6,47 $
0,00%
Sinovac Biotech Chart

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors. Attorney Advertising.  Prior results do not guarantee a similar outcome.

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      Kevin Chan, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 34th Floor
      New York, NY  10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      lrosen@rosenlegal.com
      pkim@rosenlegal.com
      kchan@rosenlegal.com
      www.rosenlegal.com

View original content with multimedia:http://www.prnewswire.com/news-releases/sinovac-loss-notice-rosen-law-firm-reminds-sinovac-biotech-ltd-investors-of-important-deadline-in-first-filed-class-action---sva-300507415.html

SOURCE Rosen Law Firm, P.A.

Werbung

Mehr Nachrichten zur Sinovac Biotech Aktie kostenlos abonnieren

E-Mail-Adresse
Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.


Andere Nutzer interessierten sich auch für folgende News